{"preliminary_commentary":{"by_channel":{"youtube":3,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["lenvatinib","everolimus"]],"indication":"metastatic clear cell renal cell carcinoma","name":"NCT05012371","nct_id":"NCT05012371","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05012371. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive lenvatinib PO QD and everolimus PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.","label":"Arm A (lenvatinib, everolimus)","type":"EXPERIMENTAL"},{"description":"Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.","label":"Arm B (cabozantinib)","type":"ACTIVE_COMPARATOR"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2027-10-25","type":"ESTIMATED"},"conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":90,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Cabozantinib","otherNames":[],"type":"DRUG"},{"name":"Everolimus","otherNames":["42-O-(2-Hydroxy)ethyl Rapamycin","Afinitor","Certican","RAD 001","RAD001","Votubia","Zortress"],"type":"DRUG"},{"name":"Lenvatinib","otherNames":["E7080","ER-203492-00","Multi-Kinase Inhibitor E7080"],"type":"DRUG"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-09-14","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib in Patients With Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-25","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Time from start of study drug until disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, assessed up to 2 years"}],"references":[],"start_date":{"date":"2022-02-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","url":"https://clinicaltrials.gov/study/NCT05012371"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05012371"}